Video

Dr. Nabors on Evolving Treatment Options for Brain Metastases

Louis B. Nabors, MD, of University of Alabama, Birmingham Comprehensive Cancer Center, discusses the evolving treatment landscape for patients with brain metastases.

Louis B. Nabors, MD, professor, University of Alabama, Birmingham Comprehensive Cancer Center, discusses the evolving treatment landscape for patients with brain metastases. For decades, as treatment for patients with brain metastases, physicians mainly relied on neurosurgery and radiation, and there were limited systemic therapy options.

Today, there is an increasing amount of systemic therapy options, says Nabors. These therapies have clearly demonstrated activity in metastatic disease in the central nervous system, he adds.

Research continues to focus on further developing these opportunities to better understand how to deploy systemic therapies in these patients. This will be a major goal over the next several years, he concludes.

<<< 2019 NCCN Annual Meeting

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie